Company: AZN
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001654954-25-010847
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-09-17
Form: 6-K
Chunk 5
---
us. Available at: https://www.cdc.gov/lupus/signs-symptoms/index.html. [Last accessed: September 2025].

9. American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis & Rheumatology. 1999;42:1785-1796.

10. Touma Z, et al. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4:e000239.

11. Izmirly PM, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991-996.

12. Apostolopoulos D & Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017;56(Suppl 1):i114-22.

13. Ji L et al. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology. 2021;60:5517-26.

14. Lateef A & Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(Suppl 4):S4.

15. American College of Rheumatology. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus (SLE). Available at: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltec93920aad624e33/sle-guideline-summary-2025.pdf. [Last accessed: September 2025].

16. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024; 83: 15-29.

17. AstraZeneca data on file. 2025. REF-288361.

18. Bruce IN, et al. Factors associated with damage accrual in patients with systemic lupus erythematos